Last update: Jan. 15, 2020

C14 H14 N2

Low Risk for breastfeeding


Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.

A sympathomimetic with alpha-adrenergic activity. It has a vasoconstrictor effect that reduces mucosal swelling and congestion.
Topical nasal use (single dose) or ophthalmological (2-4 times a day).

Since the last update we have not found published data in relation to breastfeeding.

The small dose and the low plasma absorption of most topical nasal or ophthalmological preparations make transfer into breastmilk in significant amounts unlikely.

Do not exceed the recommended dose and time periods in order to avoid undesirable side effects and the possible decrease in milk cited by some authors (Nice 2000) for other similar drugs, although not proven in practice.

It is a product which has very little literature and almost none related to pharmacokinetics.
As a nasal decongestant, it is discouraged by some authors (Nice 2000), with better known drugs from the same group being preferred (Anderson 2000).

Ophthalmic administration is fully compatible with breastfeeding. Absorption can be minimized by pressing on the tear duct (medial canthus of the eye) with your finger for 1 minute.

Accidental oral intake of naphazoline is very dangerous in children, and can cause neurological and cardiovascular disorders, and coma (Diaz 2018, Paricio 1993).

Some authors consider decongestant drugs administered orally and nasally to be non-essential medications, to be avoided in general, not only during breastfeeding, since they expose patients to serious risks (cardiovascular, neurological and intestinal) for the treatment of benign disorders such as nasal obstruction, which usually evolves favourably in a few days without medication (Prescrire 2018).

Alternatives

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

C14 H14 N2 is Naphazoline in Molecular formula.

Is written in other languages:

C14 H14 N2 is also known as

Tradenames

Main tradenames from several countries containing C14 H14 N2 in its composition:

Pharmacokinetics

Variable Value Unit
Molecular weight 247 daltons
T1/2 4 - 12 hours

References

  1. Redaction Prescrire. Pour mieux soigner, des médicaments à écarter : bilan 2018. Prescrire.org. 2018 Full text (link to original source) Full text (in our servers)
  2. Díaz M, Granson E, Taiman J, Alava J, Gabrielli T, Mendoza L. [Severe poisoning with naphazoline: update from a therapeutic error]. Arch Argent Pediatr. 2018 Aug 1;116(4):e626-e629. Abstract
  3. Nice FJ, Snyder JL, Kotansky BC. Breastfeeding and over-the-counter medications. J Hum Lact. 2000 Nov;16(4):319-31. Review. Erratum in: J Hum Lact 2001 Feb;17(1):90. Abstract
  4. Anderson PO. Decongestants and milk production. J Hum Lact. 2000 Abstract
  5. Paricio JM, Benlloch MJ, Llobat T, Santos L, Grieco M, Martín J, Soler E, Cuenca A. Intoxicación por tetraborato de sodio y nafazolina (euboral oftálmico). A propósito de un caso. Rev Esp Pediatr 1993;49:281–282. Full text (in our servers)

Total visits

178

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by La Liga de la Leche, España from Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM